Summary

Clinical Trials Treatment

The FDA approved a new targeted drug for adults with advanced non-small cell lung cancer that has a gene change called a ROS1 fusion, and whose cancer kept growing after treatment with an earlier ROS1 drug.

The U.S. Food and Drug Administration (FDA) approved a new targeted drug, zidesamtinib (Jideytro), on July 22, 2026. It is for adults with advanced non-small cell lung cancer that has a gene change called a ROS1 fusion, and whose cancer kept growing after treatment with an earlier ROS1 drug.

A ROS1 fuion happens when part of one gene breaks off and joins another gene, causing cells to grow out of control. It’s found more often in women, people who have never smoked, and people in their 30s to 50s. A tumor biomarker test is how doctors find it.

Targeted drugs for tumor mutations like ROS1 can work well, but over time many tumors find a way around them. This drug was designed to keep working when that happens. This new drug can also reach the brain, where lung cancer often spreads, was built to avoid the dizziness and other nerve-related side effects that some older ROS1 drugs can cause.

In the ARROS-1 study, 117 people whose cancer had grown after earlier ROS1 treatment took zidesamtinib. Tumors shrank in 44% of them. Among people who responded, 69% were still responding a year later. Only 2% stopped the drug because of side effects. Common side effects included swelling in the hands and feet, constipation, taste changes and tingling in the arms or legs.

One patient joined the trial at Memorial Sloan Kettering when his cancer started growing again. On zidesamtinib, his tumors shrank.

Whf you have non-small cell lung cancer, ask your care team whether your tumor has had complete biomarker testing. If you have ROS1-positive lung cancer that has stopped responding to treatment, ask whether zidesamtinib could be an option.

Read Full Article